The Regulation of Ovulation Rate and Ovarian Function by Oocyte-glycoproteins by Williams, S

Activation of human dendritic cells for immunotherapy in ovarian carcinoma by Brencicova, E, Jagger, A, Evans, H, Laios, A, Montalto, S, Ahmed, A, Raju-Kankipati, S, Taams, L, Diebold, S

C-reactive protein concentrations and subsequent ovarian cancer risk. by McSorley, M, Alberg, A, Allen, D, Allen, N, Brinton, L, Dorgan, J, Pollak, M, Tao, Y, Helzlsouer, K

“…CONCLUSION: Higher circulating CRP concentrations in women who subsequently developed ovarian cancer support the hypothesized role of chronic inflammation in ovarian carcinogenesis. …”

Differential microma expression in primary peritoneal serous carcinoma versus ovarian serous by O'Leary, J, Smyth, P, Laios, A, O'Toole, S, Russell, S, Li, J, Denning, K, Aherne, S, Ring, M, Martin, C, Sheppard, B, Lao, K, Sheils, O, Flavin, R

Histological type as a predictor of ovarian cancer survival in the million women study by Hermon, C, Beral, V, Reeves, G, Green, J, Gaitskell, K

MicroRNA gene expression profiling in human ovarian and primary peritoneal serous carcinomas by Flavin, R, O'Toole, S, Smyth, P, Laois, A, Cahill, S, Li, J, Denning, K, Martin, C, Finn, S, Shepherd, B, Lao, K, Sheils, O, O'Leary, J

MicroRNA gene expression profiling in human ovarian and primary peritoneal serous carcinomas by Flavin, R, O'Toole, S, Smyth, P, Laois, A, Cahill, S, Li, J, Denning, K, Martin, C, Finn, S, Shepherd, B, Lao, K, Sheils, O, O'Leary, J

Differential microrna expression in primary peritoneal serous carcinoma versus ovarian serous carcinoma by O'Leary, J, Smyth, P, Laios, A, O'Toole, S, Russell, S, Li, J, Denning, K, Aherne, S, Ring, M, Martin, C, Sheppard, B, Lao, K, Sheils, O, Flavin, R

Harveian Oration 2012: Halving premature death by Peto, R

MIR-29B expression is associated with disease-free survival in ovarian serous carcinoma patients by Flavin, R, Smyth, P, Barrett, C, Russell, S, Wen, H, Wei, J, Laios, A, OToole, S, Ring, M, Denning, K, Li, J, Aherne, S, Sammarae, D, Aziz, N, Alhadi, A, Finn, S, Loda, M, Sheppard, B, Sheils, O, OLeary, J

Arabic oration in early Islam: religion, ritual, and rhetoric by Qutbuddin, T

Quality of life of weekly, dose-dense versus standard chemotherapy for ovarian cancer in the ICON8 study by Blagden, S, Cook, A, Poole, C, Howells, L, McNeish, I, Dean, A, Galardo, D, Kim, J, O'Donnell, D, Hook, J, James, E, Perren, T, Lord, R, Dark, G, Earl, H, Hall, M, Kaplan, R, Ledermann, J, Clamp, A

Co-culture of ovarian cancer cells with macrophages induces expression of a scavenger receptor A ligand by Hagemann, T, Pluddemann, A, Mukhopadhyay, S, Gordon, S, Balkwilll, F

Ovarian follicle flushing as a means of increasing the yield of oocytes and in vitro produced embryos in advanced cattle breeding by Simmons, RJ, Tutt, DAR, Kwong, WY, Baroni, JI, Lim, LN, Cimpeanu, R, Castrejon-Pita, AA, Vatish, M, Svensson, P, Hagby, U, Sinclair, KD, Georgiou, EX

OCTOVA: A randomised phase II trial of olaparib, chemotherapy, or olaparib and cediranib in patients with BRCA-mutated platinumresistant ovarian cancer by Nicum, S, Strauss, V, McGregor, N, McNeish, I, Roux, R, Hall, M, Michael, A, Roberts, C

“…Women with platinum resistant ovarian cancer (OC) have limited responses to standard therapy, and clinical trials with novel agents are therefore highly justified. …”

The immunopathogenesis of ovarian teratoma-associated NMDAR-antibody encephalitis: mechanisms of B Cell immunoreactions inform a rational approach to gynaecologic operative management by Al-Diwani, A, Harrison, R, Handel, A, Irani, SR

Combretastatin A-4 phosphate (CA4P) carboplatin and paclitaxel in patients with platinum-resistant ovarian cancer: Final phase II trial results by Zweifel, M, Jayson, G, Reed, N, Osborne, R, Hassan, B, Shreeves, G, Poupard, L, Walicke, P, Balkissoon, J, Chaplin, D, Rustin, G

Response to neoadjuvant chemotherapy in ICON8: A GCIG phase III randomised trial evaluating weekly dose-dense chemotherapy integration in first-line epithelial ovarian/fallopian tube/primary peritoneal carcinoma (EOC) treatment by Clamp, A, McNeish, I, Dean, A, Gallardo-Rincon, D, Kim, J, O'Donnell, D, Hook, J, Blagden, S, Brenton, J, Naik, R, Perren, T, Sundar, S, Cook, A, James, E, Gabra, H, Lord, R, Hall, M, Dark, G, Kaplan, R, Ledermann, J

ICON8: A GCIG phase III randomised trial evaluating weekly dosedense chemotherapy integration in first- line epithelial ovarian/fallopian tube/primary peritoneal carcinoma (EOC) treatment: Results of primary progression- free survival (PFS) analysis by Clamp, A, McNeish, I, Dean, A, Gallardo, D, Weon-Kim, J, O'Donnell, D, Hook, J, Coyle, C, Blagden, S, Brenton, J, Naik, R, Perren, T, Sundar, S, Cook, A, James, E, Swart, A, Stenning, S, Kaplan, R, Ledermann, J

Single-cell RNAseq profiling of early heart developmental physiology by Miranda, AMA, Tyser, RCV, Riley, PR, Scialdone, A, Marioni, J, Srinivas, S